81 results on '"Von Pawel, J."'
Search Results
2. OA 17.07 Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study
3. P1.01-052 Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC)
4. P2.04-001 BALTIC: A Phase 2, Open-Label Study of Novel Combinations of Immunotherapies or DDR Inhibitors in Platinum-Refractory ED-SCLC
5. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK
6. Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study
7. Effect of nab-paclitaxel/carboplatin (nab-P/C) induction therapy on quality of life (QoL) of patients with squamous (SCC) non-small cell lung cancer (NSCLC) (ABOUND.sqm)
8. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK
9. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial
10. Results from OAK subgroup analyses: A randomized Phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC
11. 438O Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
12. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
13. Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study
14. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
15. 1573 Amisulpride, a dopamine D2/D3-antagonist, prevents chemotherapyinduced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin or anthracycline-cyclophosphamide regimens: A randomised, double-blind, placebo-controlled, dose-ranging trial
16. 3066 Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the randomized CEPAC-TDM study
17. Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer
18. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer
19. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
20. Effect of Nintedanib (Bibf 1120) Combined with Standard 2Nd-Line Docetaxel in Nsclc Patients Who Received Prior Pemetrexed in Lume-Lung 1: a Randomised, Placebo-Controlled Phase III Trial
21. Phase (Ph) 3 Study of Patritumab (P) Plus Erlotinib (E) in Egfr Wild-Type Subjects with Advanced Non–Small Cell Lung Cancer (Nsclc)
22. Prior Taxane Use in the Lume-Lung 1 Phase III Trial and the Effect on Outcome Following 2Nd-Line Treatment with Nintedanib (Bibf 1120) and Docetaxel in Patients with Advanced Nsclc
23. 30 Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial
24. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
25. Disrupt: A Randomized Phase 2 Trial of Ombrabulin (AVE8062) Combined with a Taxane-Platinum Regimen in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
26. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
27. Biomarker analysis in a phase III study of pemetrexed–carboplatin versus etoposide–carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
28. Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-II Study
29. 9006 ORAL Results of a Phase 2 Study of Gemcitabine/Cisplatin/lniparib (GCI) Versus Gemcitabine/cisplatin (GC) in Patients With Advanced NSCLC
30. 9000 ORAL Epidermal Growth Factor Receptor (EGFR) Expression as a Predictive Biomarker of Survival in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Therapy With Cetuximab Combined With Chemotherapy in the FLEX Trial
31. 9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy
32. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
33. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
34. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer
35. 9161 FLEX study: Prognostic factors in NSCLC
36. 9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer
37. Erlotinib: evaluation as a first-line treatment option for elderly patients with advanced non-small-cell lung cancer (NSCLC)
38. Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer
39. 6551 POSTER Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial
40. 40 POSTER Update on survival in a phase Ib/ll study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC)
41. 210 A comparison of CALGB and EORTC paradigms in the assessment of ONCONASE for the treatment of unresectable malignant mesothelioma (UMM)
42. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment
43. P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender
44. O-086 A phase III randomized trial of carboplati/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
45. P-499 Prognostic relevance of 60 clinical factors, “classical” laboratoryparameters and tumor markers in patients with advanced non-small cell lung cancer
46. PD-072 Circulating nucleosomes and cyfra 21-1 predict early theresponse to chemotherapy in patients with advanced non-small cell lung cancer
47. P-769 Prognostic relevance of 56 clinical factors, “classical” laboratoryparameters and tumor markers in patients with small cell lung cancer
48. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
49. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results
50. 789 A meta-analysis of efficacy data from two randomised studies on oral topotecan in patients with relapsed SCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.